Welcome to our dedicated page for Grail news (Ticker: GRAL), a resource for investors and traders seeking the latest updates and insights on Grail stock.
GRAIL, Inc. (Nasdaq: GRAL) is a healthcare diagnostics company whose mission is to detect cancer early, when it can be cured. The company’s news flow centers on developments related to its multi-cancer early detection (MCED) blood test, Galleri, and the targeted methylation-based platform that underpins it. GRAIL regularly reports on clinical study results, commercial collaborations, capital-raising activities, and investor events, giving readers insight into how its MCED strategy is progressing.
News updates often highlight data from large clinical studies such as PATHFINDER 2 and SYMPLIFY, where GRAIL describes Galleri’s performance when added to standard-of-care screening or used in symptomatic populations. These releases provide details on cancer detection rates, positive predictive value, specificity, cancer signal origin accuracy, and safety outcomes, as well as how Galleri may detect cancers that lack recommended screening options.
Investors and healthcare observers can also find announcements about financial results, private placements, and equity distribution arrangements, which GRAIL describes as supporting its commercial and reimbursement efforts. Additional coverage includes strategic collaborations, such as agreements with Medcan and Manulife Canada for access to Galleri, and a planned collaboration with Samsung-related entities to commercialize the test in certain Asian markets, subject to regulatory and contractual conditions.
This news page aggregates these company-issued updates so readers can follow GRAIL’s reported clinical evidence, commercial partnerships, financing transactions, and conference presentations over time.
GRAIL (Nasdaq: GRAL) submitted the final module of a Premarket Approval (PMA) application to the U.S. FDA on Jan 29, 2026 for the Galleri multi-cancer early detection test.
The filing cites performance and safety data from 25,490 PATHFINDER 2 participants and first-year data from the randomized NHS-Galleri trial, plus a bridging analysis to the PMA test version. Galleri received Breakthrough Device designation in 2018.
GRAIL (Nasdaq: GRAL) announced management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, Jan. 12, 2026 at 7:30 a.m. PT. Live and replay webcasts will be available in the investor relations section at investors.grail.com. The webcast will be archived and available for replay for at least 30 days after the event.
GRAIL (Nasdaq: GRAL) granted inducement equity awards under Nasdaq Listing Rule 5635(c)(4) to recent hires on Dec. 1, 2025. The company issued restricted stock units totaling 21,570 shares to 21 non-executive employees under its Inducement Equity Incentive Plan as an employment inducement.
The RSUs vest over an approximately four-year schedule, with 25% vesting on Nov. 30, 2026 and the remainder vesting on each one-year anniversary thereafter, subject to continued employment with GRAIL or its successor/subsidiary.
GRAIL (Nasdaq: GRAL) will present at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, Dec. 2, 2025 at 3:00 p.m. ET.
Company management's presentation will be available via live webcast and replay at investors.grail.com. The webcast will be archived and available for at least 30 days after the event.
GRAIL (Nasdaq: GRAL) reported Q3 2025 results with total revenue $36.2M (+26% YoY) and U.S. Galleri revenue $32.6M (+28% YoY). Galleri tests sold grew 39% YoY to >45,000. Q3 net loss was $89.0M and adjusted EBITDA was $(71.7)M. Adjusted gross profit improved to $20.0M.
Key corporate items: PMA submission for Galleri now anticipated in Q1 2026; completed a private placement raising ~$325M; Samsung agreed to an equity investment of $110M (subject to closing) and a strategic collaboration for Asia; cash position now >$850M, providing runway into 2030. Positive PATHFINDER 2 and SYMPLIFY data were highlighted.
GRAIL (Nasdaq: GRAL) announced that company management will present at the 7th Annual Wolfe Research Healthcare Conference on Tuesday, Nov. 18, 2025 at 10:00 a.m. ET.
Live and replay webcasts will be available via the company's investor relations site at investors.grail.com, and the webcast will be archived and available for replay for at least 30 days after the event.
GRAIL (Nasdaq: GRAL) will release its third quarter 2025 financial results after market close on Wednesday, Nov 12, 2025. Management will discuss results on a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET the same day.
GRAIL will also host Analyst Day 2025 on Tuesday, Nov 13, 2025 at its central laboratories in Research Triangle Park, NC, with the Analyst Day webcast beginning at 11:00 a.m. ET. Live webcasts and recorded replays for both events will be available in the investor relations section at investors.grail.com, and registration links are provided for the live events.
GRAIL (Nasdaq: GRAL) entered a securities purchase agreement for a private placement expected to raise approximately $325.0 million in gross proceeds by selling 4,639,543 shares of common stock (or pre-funded warrants) at $70.05 per share. The financing included new and existing institutional investors and is expected to close on October 21, 2025, subject to customary conditions.
GRAIL said it will use net proceeds for commercial activities, reimbursement efforts, working capital, and general corporate purposes, and expects current cash, equivalents and investments plus these proceeds to fund operations into 2030, excluding a separate potential $110 million Samsung investment subject to closing conditions.
GRAIL (Nasdaq: GRAL) and University of Oxford will present extended SYMPLIFY results at EDCC on Oct 21, 2025. The 24-month registry follow-up of >6,000 symptomatic participants found that 35.4% (28 of 79) initially classified as false positives were later diagnosed with cancer, raising Galleri's positive predictive value in this symptomatic cohort to 84.2% (from 75.5% in the primary analysis).
Galleri accurately predicted the Cancer Signal Origin (CSO) in 27 of 28 later-diagnosed cases, and in many instances the detected CSO differed from the original referral pathway, suggesting potential to guide more efficient diagnostic workups.
GRAIL (Nasdaq: GRAL) announced positive PATHFINDER 2 results showing the Galleri multi-cancer early detection test increased cancer detection >7-fold when added to USPSTF A and B recommended screenings.
Key metrics from 23,161 performance-analyzable participants (12-month follow-up): cancer signal in 216 (0.93%), cancer diagnosed in 133 (0.57%), PPV 61.6%, specificity 99.6% (0.4% false positive), episode sensitivity 73.7% for 12 cancers causing two-thirds of U.S. cancer deaths and 40.4% for all cancers. More than half (53.5%) of Galleri-detected new cancers were stage I–II. GRAIL plans a PMA submission in H1 2026.
FAQ
What is the current stock price of Grail (GRAL)?
What is the market cap of Grail (GRAL)?
